Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Arcellx

Arcellx
2014 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$85M LATEST DEAL AMOUNT
10 INVESTORS
Description

Operator of a privately held biopharmaceutical company intended to offer anti-tumor therapeutical services. The company develops first-in-class adaptive immune cell therapies that are readily silenced, activated and reprogrammed throughout the course of the disease, providing physicians with enhanced safety, improved efficacy and expanded utility.

Website
Formerly Known As
Encarta Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 25 West Watkins Mill Road
  • Suite A
  • Gaithersburg, MD 20878
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Arcellx’s full profile, request a free trial.

Arcellx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 14-Oct-2019 $85M 0000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 17-Jan-2017 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Arcellx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B-1 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B-2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00
Series A 29,795,227 $0.001000 8% $1 $1 1x $1 41.59%
To view this company’s complete Cap Table, request access »

Arcellx Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
AJU IB Investment Venture Capital Minority 000 0000 000000 0
JVC Investment Partners Venture Capital Minority 000 0000 000000 0
LG Technology Ventures Corporate Venture Capital Minority 000 0000 000000 0
Mirae Asset Capital Other Minority 000 0000 000000 0
Mirae Asset Venture Investment PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Arcellx Executive Team (3)

Name Title Board
Seat
Contact
Info
David Hilbert Ph.D President, Chief Executive Officer & Board Member
Han Lee Ph.D Chief Business Officer and Head of Finance
Angela Shen Chief Medical Officer

Arcellx Board Members (7)

Name Representing Role Since Contact
Info
Ali Behbahani Self Board Member 000 0000
David Hilbert Ph.D Arcellx President, Chief Executive Officer & Board Member 000 0000
Hugo Beekman AJU IB Investment Board Member 000 0000
Jill Carroll Self Board Member 000 0000
Lewis Williams Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »